The global market for Primary Myelofibrosis Drug was estimated to be worth US$ 134 million in 2023 and is forecast to a readjusted size of US$ 246.1 million by 2030 with a CAGR of 9.6% during the forecast period 2024-2030

Primary Myelofibrosis Drug - Market

Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Primary Myelofibrosis Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Primary Myelofibrosis Drug by region & country, by Type, and by Application.

The Primary Myelofibrosis Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Myelofibrosis Drug.

Market Segmentation

Scope of Primary Myelofibrosis Drug - Market Report

Report Metric	Details
Report Name	Primary Myelofibrosis Drug - Market
Forecasted market size in 2030	US$ 246.1 million
CAGR	9.6%
Forecasted years	2024 - 2030
Segment by Type:	JAK 1 JAK 2 Others
Segment by Application	Adults Children
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb, Suzhou Zelgen Biopharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Primary Myelofibrosis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Primary Myelofibrosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Primary Myelofibrosis Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Primary Myelofibrosis Drug - Market size in 2030?

Ans: The Primary Myelofibrosis Drug - Market size in 2030 will be US$ 246.1 million.

Who are the main players in the Primary Myelofibrosis Drug - Market report?

Ans: The main players in the Primary Myelofibrosis Drug - Market are GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb, Suzhou Zelgen Biopharmaceuticals

What are the Application segmentation covered in the Primary Myelofibrosis Drug - Market report?

Ans: The Applications covered in the Primary Myelofibrosis Drug - Market report are Adults, Children

What are the Type segmentation covered in the Primary Myelofibrosis Drug - Market report?

Ans: The Types covered in the Primary Myelofibrosis Drug - Market report are JAK 1, JAK 2, Others

1 Market Overview

1.1 Primary Myelofibrosis Drug Product Introduction

1.2 Global Primary Myelofibrosis Drug Market Size Forecast

1.2.1 Global Primary Myelofibrosis Drug Sales Value (2019-2030)

1.2.2 Global Primary Myelofibrosis Drug Sales Volume (2019-2030)

1.2.3 Global Primary Myelofibrosis Drug Sales Price (2019-2030)

1.3 Primary Myelofibrosis Drug Market Trends & Drivers

1.3.1 Primary Myelofibrosis Drug Industry Trends

1.3.2 Primary Myelofibrosis Drug Market Drivers & Opportunity

1.3.3 Primary Myelofibrosis Drug Market Challenges

1.3.4 Primary Myelofibrosis Drug Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Primary Myelofibrosis Drug Players Revenue Ranking (2023)

2.2 Global Primary Myelofibrosis Drug Revenue by Company (2019-2024)

2.3 Global Primary Myelofibrosis Drug Players Sales Volume Ranking (2023)

2.4 Global Primary Myelofibrosis Drug Sales Volume by Company Players (2019-2024)

2.5 Global Primary Myelofibrosis Drug Average Price by Company (2019-2024)

2.6 Key Manufacturers Primary Myelofibrosis Drug Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Primary Myelofibrosis Drug Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Primary Myelofibrosis Drug

2.9 Primary Myelofibrosis Drug Market Competitive Analysis

2.9.1 Primary Myelofibrosis Drug Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Primary Myelofibrosis Drug Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Myelofibrosis Drug as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 JAK 1

3.1.2 JAK 2

3.1.3 Others

3.2 Global Primary Myelofibrosis Drug Sales Value by Type

3.2.1 Global Primary Myelofibrosis Drug Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Primary Myelofibrosis Drug Sales Value, by Type (2019-2030)

3.2.3 Global Primary Myelofibrosis Drug Sales Value, by Type (%) (2019-2030)

3.3 Global Primary Myelofibrosis Drug Sales Volume by Type

3.3.1 Global Primary Myelofibrosis Drug Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Primary Myelofibrosis Drug Sales Volume, by Type (2019-2030)

3.3.3 Global Primary Myelofibrosis Drug Sales Volume, by Type (%) (2019-2030)

3.4 Global Primary Myelofibrosis Drug Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Adults

4.1.2 Children

4.2 Global Primary Myelofibrosis Drug Sales Value by Application

4.2.1 Global Primary Myelofibrosis Drug Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Primary Myelofibrosis Drug Sales Value, by Application (2019-2030)

4.2.3 Global Primary Myelofibrosis Drug Sales Value, by Application (%) (2019-2030)

4.3 Global Primary Myelofibrosis Drug Sales Volume by Application

4.3.1 Global Primary Myelofibrosis Drug Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Primary Myelofibrosis Drug Sales Volume, by Application (2019-2030)

4.3.3 Global Primary Myelofibrosis Drug Sales Volume, by Application (%) (2019-2030)

4.4 Global Primary Myelofibrosis Drug Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Primary Myelofibrosis Drug Sales Value by Region

5.1.1 Global Primary Myelofibrosis Drug Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Primary Myelofibrosis Drug Sales Value by Region (2019-2024)

5.1.3 Global Primary Myelofibrosis Drug Sales Value by Region (2025-2030)

5.1.4 Global Primary Myelofibrosis Drug Sales Value by Region (%), (2019-2030)

5.2 Global Primary Myelofibrosis Drug Sales Volume by Region

5.2.1 Global Primary Myelofibrosis Drug Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Primary Myelofibrosis Drug Sales Volume by Region (2019-2024)

5.2.3 Global Primary Myelofibrosis Drug Sales Volume by Region (2025-2030)

5.2.4 Global Primary Myelofibrosis Drug Sales Volume by Region (%), (2019-2030)

5.3 Global Primary Myelofibrosis Drug Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Primary Myelofibrosis Drug Sales Value, 2019-2030

5.4.2 North America Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Primary Myelofibrosis Drug Sales Value, 2019-2030

5.5.2 Europe Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Primary Myelofibrosis Drug Sales Value, 2019-2030

5.6.2 Asia Pacific Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Primary Myelofibrosis Drug Sales Value, 2019-2030

5.7.2 South America Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Primary Myelofibrosis Drug Sales Value, 2019-2030

5.8.2 Middle East & Africa Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Primary Myelofibrosis Drug Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Primary Myelofibrosis Drug Sales Value

6.2.1 Key Countries/Regions Primary Myelofibrosis Drug Sales Value, 2019-2030

6.2.2 Key Countries/Regions Primary Myelofibrosis Drug Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Primary Myelofibrosis Drug Sales Value, 2019-2030

6.3.2 United States Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Primary Myelofibrosis Drug Sales Value, 2019-2030

6.4.2 Europe Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Primary Myelofibrosis Drug Sales Value, 2019-2030

6.5.2 China Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.5.3 China Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Primary Myelofibrosis Drug Sales Value, 2019-2030

6.6.2 Japan Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Primary Myelofibrosis Drug Sales Value, 2019-2030

6.7.2 South Korea Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Primary Myelofibrosis Drug Sales Value, 2019-2030

6.8.2 Southeast Asia Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Primary Myelofibrosis Drug Sales Value, 2019-2030

6.9.2 India Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

6.9.3 India Primary Myelofibrosis Drug Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 GSK

7.1.1 GSK Company Information

7.1.2 GSK Introduction and Business Overview

7.1.3 GSK Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.1.4 GSK Primary Myelofibrosis Drug Product Offerings

7.1.5 GSK Recent Development

7.2 AbbVie

7.2.1 AbbVie Company Information

7.2.2 AbbVie Introduction and Business Overview

7.2.3 AbbVie Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.2.4 AbbVie Primary Myelofibrosis Drug Product Offerings

7.2.5 AbbVie Recent Development

7.3 Novartis

7.3.1 Novartis Company Information

7.3.2 Novartis Introduction and Business Overview

7.3.3 Novartis Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Novartis Primary Myelofibrosis Drug Product Offerings

7.3.5 Novartis Recent Development

7.4 Celgene

7.4.1 Celgene Company Information

7.4.2 Celgene Introduction and Business Overview

7.4.3 Celgene Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Celgene Primary Myelofibrosis Drug Product Offerings

7.4.5 Celgene Recent Development

7.5 Grunenthal

7.5.1 Grunenthal Company Information

7.5.2 Grunenthal Introduction and Business Overview

7.5.3 Grunenthal Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Grunenthal Primary Myelofibrosis Drug Product Offerings

7.5.5 Grunenthal Recent Development

7.6 Incyte

7.6.1 Incyte Company Information

7.6.2 Incyte Introduction and Business Overview

7.6.3 Incyte Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Incyte Primary Myelofibrosis Drug Product Offerings

7.6.5 Incyte Recent Development

7.7 CTI BioPharma

7.7.1 CTI BioPharma Company Information

7.7.2 CTI BioPharma Introduction and Business Overview

7.7.3 CTI BioPharma Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.7.4 CTI BioPharma Primary Myelofibrosis Drug Product Offerings

7.7.5 CTI BioPharma Recent Development

7.8 Bristol Myers Squibb

7.8.1 Bristol Myers Squibb Company Information

7.8.2 Bristol Myers Squibb Introduction and Business Overview

7.8.3 Bristol Myers Squibb Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Bristol Myers Squibb Primary Myelofibrosis Drug Product Offerings

7.8.5 Bristol Myers Squibb Recent Development

7.9 Suzhou Zelgen Biopharmaceuticals

7.9.1 Suzhou Zelgen Biopharmaceuticals Company Information

7.9.2 Suzhou Zelgen Biopharmaceuticals Introduction and Business Overview

7.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product Offerings

7.9.5 Suzhou Zelgen Biopharmaceuticals Recent Development

8 Industry Chain Analysis

8.1 Primary Myelofibrosis Drug Industrial Chain

8.2 Primary Myelofibrosis Drug Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Primary Myelofibrosis Drug Sales Model

8.5.2 Sales Channel

8.5.3 Primary Myelofibrosis Drug Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Suzhou Zelgen Biopharmaceuticals

List of Tables

Table 1. Primary Myelofibrosis Drug Market Trends

Table 2. Primary Myelofibrosis Drug Market Drivers & Opportunity

Table 3. Primary Myelofibrosis Drug Market Challenges

Table 4. Primary Myelofibrosis Drug Market Restraints

Table 5. Global Primary Myelofibrosis Drug Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Primary Myelofibrosis Drug Revenue Market Share by Company (2019-2024)

Table 7. Global Primary Myelofibrosis Drug Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Primary Myelofibrosis Drug Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Primary Myelofibrosis Drug Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Primary Myelofibrosis Drug Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Primary Myelofibrosis Drug Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Primary Myelofibrosis Drug

Table 13. Global Primary Myelofibrosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Myelofibrosis Drug as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Primary Myelofibrosis Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Primary Myelofibrosis Drug Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Primary Myelofibrosis Drug Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Primary Myelofibrosis Drug Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Primary Myelofibrosis Drug Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Primary Myelofibrosis Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Primary Myelofibrosis Drug Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Primary Myelofibrosis Drug Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Primary Myelofibrosis Drug Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Primary Myelofibrosis Drug Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Primary Myelofibrosis Drug Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Primary Myelofibrosis Drug Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Primary Myelofibrosis Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Primary Myelofibrosis Drug Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Primary Myelofibrosis Drug Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Primary Myelofibrosis Drug Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Primary Myelofibrosis Drug Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Primary Myelofibrosis Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Primary Myelofibrosis Drug Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Primary Myelofibrosis Drug Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Primary Myelofibrosis Drug Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Primary Myelofibrosis Drug Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Primary Myelofibrosis Drug Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Primary Myelofibrosis Drug Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Primary Myelofibrosis Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Primary Myelofibrosis Drug Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Primary Myelofibrosis Drug Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Primary Myelofibrosis Drug Sales Value by Region (2019-2024) & (%)

Table 44. Global Primary Myelofibrosis Drug Sales Value by Region (2025-2030) & (%)

Table 45. Global Primary Myelofibrosis Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Primary Myelofibrosis Drug Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Primary Myelofibrosis Drug Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Primary Myelofibrosis Drug Sales Volume by Region (2019-2024) & (%)

Table 49. Global Primary Myelofibrosis Drug Sales Volume by Region (2025-2030) & (%)

Table 50. Global Primary Myelofibrosis Drug Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Primary Myelofibrosis Drug Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Primary Myelofibrosis Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Primary Myelofibrosis Drug Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Primary Myelofibrosis Drug Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Primary Myelofibrosis Drug Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Primary Myelofibrosis Drug Sales Volume, (2025-2030) & (K Units)

Table 57. GSK Company Information

Table 58. GSK Introduction and Business Overview

Table 59. GSK Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. GSK Primary Myelofibrosis Drug Product Offerings

Table 61. GSK Recent Development

Table 62. AbbVie Company Information

Table 63. AbbVie Introduction and Business Overview

Table 64. AbbVie Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. AbbVie Primary Myelofibrosis Drug Product Offerings

Table 66. AbbVie Recent Development

Table 67. Novartis Company Information

Table 68. Novartis Introduction and Business Overview

Table 69. Novartis Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Novartis Primary Myelofibrosis Drug Product Offerings

Table 71. Novartis Recent Development

Table 72. Celgene Company Information

Table 73. Celgene Introduction and Business Overview

Table 74. Celgene Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Celgene Primary Myelofibrosis Drug Product Offerings

Table 76. Celgene Recent Development

Table 77. Grunenthal Company Information

Table 78. Grunenthal Introduction and Business Overview

Table 79. Grunenthal Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Grunenthal Primary Myelofibrosis Drug Product Offerings

Table 81. Grunenthal Recent Development

Table 82. Incyte Company Information

Table 83. Incyte Introduction and Business Overview

Table 84. Incyte Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Incyte Primary Myelofibrosis Drug Product Offerings

Table 86. Incyte Recent Development

Table 87. CTI BioPharma Company Information

Table 88. CTI BioPharma Introduction and Business Overview

Table 89. CTI BioPharma Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. CTI BioPharma Primary Myelofibrosis Drug Product Offerings

Table 91. CTI BioPharma Recent Development

Table 92. Bristol Myers Squibb Company Information

Table 93. Bristol Myers Squibb Introduction and Business Overview

Table 94. Bristol Myers Squibb Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Bristol Myers Squibb Primary Myelofibrosis Drug Product Offerings

Table 96. Bristol Myers Squibb Recent Development

Table 97. Suzhou Zelgen Biopharmaceuticals Company Information

Table 98. Suzhou Zelgen Biopharmaceuticals Introduction and Business Overview

Table 99. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product Offerings

Table 101. Suzhou Zelgen Biopharmaceuticals Recent Development

Table 102. Key Raw Materials Lists

Table 103. Raw Materials Key Suppliers Lists

Table 104. Primary Myelofibrosis Drug Downstream Customers

Table 105. Primary Myelofibrosis Drug Distributors List

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

List of Figures

Figure 1. Primary Myelofibrosis Drug Product Picture

Figure 2. Global Primary Myelofibrosis Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Primary Myelofibrosis Drug Sales Volume (2019-2030) & (K Units)

Figure 5. Global Primary Myelofibrosis Drug Sales Price (2019-2030) & (US$/Unit)

Figure 6. Primary Myelofibrosis Drug Report Years Considered

Figure 7. Global Primary Myelofibrosis Drug Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Primary Myelofibrosis Drug Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Primary Myelofibrosis Drug Revenue in 2023

Figure 10. Primary Myelofibrosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. JAK 1 Picture

Figure 12. JAK 2 Picture

Figure 13. Others Picture

Figure 14. Global Primary Myelofibrosis Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Primary Myelofibrosis Drug Sales Value Market Share by Type, 2023 & 2030

Figure 16. Global Primary Myelofibrosis Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 17. Global Primary Myelofibrosis Drug Sales Volume Market Share by Type, 2023 & 2030

Figure 18. Global Primary Myelofibrosis Drug Price by Type (2019-2030) & (US$/Unit)

Figure 19. Product Picture of Adults

Figure 20. Product Picture of Children

Figure 21. Global Primary Myelofibrosis Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 22. Global Primary Myelofibrosis Drug Sales Value Market Share by Application, 2023 & 2030

Figure 23. Global Primary Myelofibrosis Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 24. Global Primary Myelofibrosis Drug Sales Volume Market Share by Application, 2023 & 2030

Figure 25. Global Primary Myelofibrosis Drug Price by Application (2019-2030) & (US$/Unit)

Figure 26. North America Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 27. North America Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

Figure 28. Europe Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 29. Europe Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

Figure 30. Asia Pacific Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

Figure 32. South America Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 33. South America Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

Figure 34. Middle East & Africa Primary Myelofibrosis Drug Sales Value (2019-2030) & (US$ Million)

Figure 35. Middle East & Africa Primary Myelofibrosis Drug Sales Value by Country (%), 2023 VS 2030

Figure 36. Key Countries/Regions Primary Myelofibrosis Drug Sales Value (%), (2019-2030)

Figure 37. Key Countries/Regions Primary Myelofibrosis Drug Sales Volume (%), (2019-2030)

Figure 38. United States Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 39. United States Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 40. United States Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 41. Europe Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 42. Europe Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 43. Europe Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 44. China Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 45. China Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 46. China Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 47. Japan Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 48. Japan Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 49. Japan Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 50. South Korea Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 51. South Korea Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 52. South Korea Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 53. Southeast Asia Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 54. Southeast Asia Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 55. Southeast Asia Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 56. India Primary Myelofibrosis Drug Sales Value, (2019-2030) & (US$ Million)

Figure 57. India Primary Myelofibrosis Drug Sales Value by Type (%), 2023 VS 2030

Figure 58. India Primary Myelofibrosis Drug Sales Value by Application (%), 2023 VS 2030

Figure 59. Primary Myelofibrosis Drug Industrial Chain

Figure 60. Primary Myelofibrosis Drug Manufacturing Cost Structure

Figure 61. Channels of Distribution (Direct Sales, and Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-26D6003

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Global Chemotherapy Chairs Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-26D13514

Sat Oct 12 00:00:00 UTC 2024

Add to Cart

Drugs for Non-Small Cell Lung Cancer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-33S12067

Fri Oct 11 00:00:00 UTC 2024

Add to Cart

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Primary Myelofibrosis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-13V14128

Primary Myelofibrosis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Primary Myelofibrosis Drug - Market Size

Primary Myelofibrosis Drug - Market

Report Scope

Scope of Primary Myelofibrosis Drug - Market Report

Chapter Outline

FAQ for this report

What is the Primary Myelofibrosis Drug - Market size in 2030?

Who are the main players in the Primary Myelofibrosis Drug - Market report?

What are the Application segmentation covered in the Primary Myelofibrosis Drug - Market report?

What are the Type segmentation covered in the Primary Myelofibrosis Drug - Market report?

FEATURED COMPANIES

RELATED REPORTS